TFCP
TPST icon

Twin Focus Capital Partners’s Tempest Therapeutics TPST Stock Holding History

Twin Focus Capital Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-332
Closed -$515K – 105
2018
Q4 		$515K Buy
+332
New +$683K 0.23% 59

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Twin Focus Capital Partners's TPST Position: Q1 2019 in Review

Twin Focus Capital Partners sold out of Tempest Therapeutics (TPST) in Q1 2019, closing a stake of 332 shares — an estimated $515K sold.

Twin Focus Capital Partners first reported a position in TPST in Q4 2018 and held it in 1 quarter. The position peaked at $515K in Q4 2018. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2019.

  • Twin Focus Capital Partners reported no remaining Tempest Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Twin Focus Capital Partners sold 332 Tempest Therapeutics shares in Q1 2019, an estimated $515K.
  • Twin Focus Capital Partners first reported a position in Tempest Therapeutics in Q4 2018 and held it in 1 quarter.
  • Twin Focus Capital Partners's Tempest Therapeutics position peaked at $515K in Q4 2018.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2019.

Based on Twin Focus Capital Partners's 13F filing for Q1 2019, filed 14 May 2019.